Neuren and ACADIA announce agreement for North America
Filed with ASX · · 5 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Announcement of buy-back - Appendix 3C
- Neuren announces investment and exclusive negotiation period
- First patent in Japan granted for Neurens trofinetide
- Disclosure under Listing Rule 4.3D
- S&P DJ Indices Announces March Quarterly Rebalance
Later from Neuren Pharmaceuticals
- Neuren receives initial payment of US$10 million from ACADIA
- Neuren and Lanstead agree to pause settlements for 120 days
- Trofinetide ex-North America exclusive negotiation period
- NNZ-2591 positive effects in Phelan-McDermid syndrome model
- Preliminary Final Report and statutory accounts
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals